Hepatocellular carcinoma and hepatitis C in the United States

Hepatology

Volumn 36, Issue 5 I, 2002, Pages

  El Serag, Hashem B ^a  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT;

AGE; ALCOHOL CONSUMPTION; BLOOD TRANSFUSION; CONFERENCE PAPER; DIABETES MELLITUS; DISEASE PREDISPOSITION; EARLY DIAGNOSIS; ETHNOLOGY; GENDER; HEPATITIS B; HEPATITIS C; HUMAN; INCIDENCE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR; UNITED STATES;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; HEPATITIS C; HUMANS; INCIDENCE; LIVER NEOPLASMS; RISK FACTORS; UNITED STATES;

EID: 0036829856     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2002.36807     Document Type: Conference Paper

References (88)

1. Sherlock S. Viruses and hepatocellular carcinoma. Gut 1994;35:828-832.
2. Colombo M. Hepatitis C virus and hepatocellular carcinoma. Baillieres Best Pract Res Clin Gastroenterol 1999;13:519-528.
3. Colombo M, Kuo G, Choo QL, Donato MF, Del Ninno E, Tommasini MA, et al. Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet 1989;2:1006-1008.
4. Fasani P, Sangiovanni A, De Fazio C, Borzio M, Bruno S, Ronchi G, et al. High prevalence of multinodular hepatocellular carcinoma in patients with cirrhosis attributable to multiple risk factors. Hepatology 1999;29:1704-1707.
5. Stroffolini T, Andreone P, Andriulli A, Ascione A, Craxi A, Chiaramonte M, et al. Gross pathologic types of hepatocellular carcinoma in Italy. Oncology 1999;56:189-192.
6. Deuffic S, Poynard T, Buffat L, Valleron AJ. Trends in primary liver cancer. Lancet 1998;351:214-215.
7. Bruix J, Barrera JM, Calvet X, Ercilla G, Costa J, Sanchez-Tapias JM, et al. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet 1989;2:1004-1006.
8. Okuda K, Fujimoto I, Hanai A, Urano Y. Changing incidence of hepatocellular carcinoma in Japan. Cancer Res 1987;47:4967-4972.
9. Yoshizawa H. Hepatocellular carcinoma associated with hepatitis C virus infection in Japan: Projection to other countries in the foreseeable future. Oncology 2002;62(Suppl 1):8-17.
10. Deuffic S, Poynard TVA. Correlation between hepatitis virus prevalence and hepatocellular carcinoma mortality in Europe. J Virol Hepat 1999;6:411-413.
11. Sallie R, Di Bisceglie AM. Viral hepatitis and hepatocellular carcinoma. Gastroenterol Clin North Am 1994;23:567-579.
12. Hasan F, Jeffers LJ, De Medina M, Reddy KR, Parker T, Schiff ER, et al. Hepatitis C-associated hepatocellular carcinoma. Hepatology 1990;12:589-591.
13. Yu MC, Tong MJ, Coursaget P, Ross RK, Govindarajan S, Henderson BE. Prevalence of hepatitis B and C viral markers in black and white patients with hepatocellular carcinoma in the United States. J Natl Cancer Inst 1990;82:1038-1041.
14. El Serag HB, Richardson PA, Everhart JE. The role of diabetes in hepatocellular carcinoma: A case-control study among United States Veterans. Am J Gastroenterol 2001;96:2462-2467.
15. Hassan M, Fromm A, Part YZ, El-Serag HB. The rising prevalence of hepatitis C infection among patients recently diagnosed with hepatocellular carcinoma in the United States. J Clin Gastroenterol 2002 (in press).
16. Liang TJ, Jeffers LJ, Reddy KR, De Medina M, Parker IT, Cheinquer H, et al. Viral pathogenesis of hepatocellular carcinoma in the United States. Hepatology 1993;18:1326-1333.
17. Fattovich G. Progression of hepatitis B and C to hepatocellular carcinoma in Western countries. Hepatogastroenterology 1998;45:1206-1213.
18. De Mitri MS, Poussin K, Baccarini P, Pontisso P, D'Errico A, Simon N, et al. HCV-associated liver cancer without cirrhosis. Lancet 1995;345:413-415.
19. Bralet MP, Regimbeau JM, Pineau P, Dubois S, Loas G, Degos F, et al. Hepatocellular carcinoma occurring in nonfibrotic liver: Epidemiologic and histopathologic analysis of 80 French cases. Hepatology 2000;32:200-204.
20. Tong MJ, el Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995;332:1463-1466.
21. Kiyosawa K, Tanaka E, Sodeyama T. Hepatitis C virus and hepatocellular carcinoma. In: Reesink HW, ed. Hepatitis C Virus. New York, NY: Karger, 1998;161-180.
22. Castells L, Vargas V, Gonzalez A, Esteban J, Esteban R, Guardia J. Long interval between HCV infection and development of hepatocellular carcinoma. Liver 1995;15:159-163.
23. Resnick RH, Koff R. Hepatitis C-related hepatocellular carcinoma. Prevalence and significance. Arch Intern Med 1993;153:1672-1677.
24. Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 1998;75:347-354.
25. Di Bisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH, Melpolder JJ, Alter HJ. Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology 1991;14:969-974.
26. Seeff LB. Natural history of hepatitis C. Am J Med 1999;107:10S-15S.
27. El-Serag HB, Goodgame B, Shaheen N. The risk of cirrhosis and hepatocellular carcinoma (HCC) among HCV-infected patients: A systematic review. Gastroenterology 2002;123:S50.
28. Freeman AJ, Dore GJ, Law MG, Thorpe M, Von Overbeck J, Lloyd AR, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001;34:809-816.
29. Everhart J, Herion D. Hepatitis C virus infection and alcohol. In: Liang TJ, Hoofnagle JH, eds. Hepatitis C. San Diego: Academic Press, 2000;363-388.
30. Cramp ME. HBV + HCV = HCC? Gut 1999;45:168-169.
31. Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: A meta-analysis. Clin Infect Dis 2001;33:562-569.
32. Donato F, Tagger A, Gelatti U, Parrinello G, Boffetta P, Albertini A, et al. Alcohol and hepatocellular carcinoma: The effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 2002;155:323-331.
33. Donato F, Tagger A, Chiesa R, Ribero ML, Tomasoni V, Fasola M, et al. Hepatitis B and C virus infection, alcohol drinking, and hepatocellular carcinoma: A case-control study in Italy. Brescia HCC Study. Hepatology 1997;26:579-584.
34. Chiba T, Matsuzaki Y, Abei M, Shoda J, Aikawa T, Tanaka N, et al. Multivariate analysis of risk factors for hepatocellular carcinoma in patients with hepatitis C virus-related liver cirrhosis. J Gastroenterol 1996;31:552-558.
35. Simonetti RG, Camma C, Fiorello F, Cottone M, Rapicetta M, Marino L, et al. Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis. A case-control study. Ann Intern Med 1992;116:97-102.
36. Miyakawa H, Izumi N, Marumo F, Sato C. Roles of alcohol, hepatitis virus infection, and gender in the development of hepatocellular carcinoma in patients with liver cirrhosis. Alcohol Clin Exp Res 1996;20(Suppl 1):91A-94A.
37. Makris M, Preston FE, Rosendaal FR, Underwood JC, Rice KM, Triger DR. The natural history of chronic hepatitis C in haemophiliacs. Br J Haematol 1996;94:746-752.
38. Tradati F, Colombo M, Mannucci PM, Rumi MG, De Fazio C, Gamba G, et al. A prospective multicenter study of hepatocellular carcinoma in Italian hemophiliacs with chronic hepatitis C. The Study Group of the Association of Italian Hemophilia Centers. Blood 1998;91:1173-1177.
39. Braga C, La Vecchia C, Negri E, Franceschi S. Attributable risks for hepatocellular carcinoma in northern Italy. Eur J Cancer 1997;33:629-634.
40. Yu MC, Tong MJ, Govindarajan S, Henderson BE. Nonviral risk factors for hepatocellular carcinoma in a low-risk population, the non-Asians of Los Angeles County, California. J Natl Cancer Inst 1991;83:1820-1826.
41. La Vecchia C, Negri E, Decarli A, Franceschi S. Diabetes mellitus and the risk of primary liver cancer. Int J Cancer 1997;73:204-207.
42. Adami HO, Chow WH, Nyren O, Berne C, Linet MS, Ekbom A, et al. Excess risk of primary liver cancer in patients with diabetes mellitus. J Natl Cancer Inst 1996;88:1472-1477.
43. Lagiou P, Kuper H, Stuver SO, Tzonou A, Trichopoulos D, Adami HO. Role of diabetes mellitus in the etiology of hepatocellular carcinoma. J Natl Cancer Inst 2000;92:1096-1099.
44. Lu SN, Lin TM, Chen CJ, Chen JS, Liaw YF, Chang WY, et al. A case-control study of primary hepatocellular carcinoma in Taiwan. Cancer 1988;62:2051-2055.
45. Reid AE. Nonalcoholic steatohepatitis. Gastroenterology 2001;121:710-723.
46. Moore MA, Park CB, Tsuda H. Implications of the hyperinsulinaemia-diabetes-cancer link for preventive efforts. Eur J Cancer Prev 1998;7:89-107.
47. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001;33:1358-1364.
48. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: Clinical characterization and risk factors for underlying disease. Hepatology 1999;29:664-669.
49. Bruno S, Silini E, Crosignani A, Borzio F, Leandro G, Bono F, et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: A prospective study. Hepatology 1997;25:754-758.
50. Murase J, Kubo S, Nishiguchi S, Hirohashi K, Shuto T, Ikebe T, et al. Correlation of clinicopathologic features of resected hepatocellular carcinoma with hepatitis C virus genotype. Jpn J Cancer Res 1999;90:1293-1300.
51. Lopez-Labrador FX, Ampurdanes S, Forns X, Castells A, Saiz JC, Costa J, et al. Hepatitis C virus (HCV) genotypes in Spanish patients with HCV infection: Relationship between HCV genotype 1b, cirrhosis and hepatocellular carcinoma. J Hepatol 1997;27:959-965.
52. Gordon SC, Bayati N, Silverman AL. Clinical outcome of hepatitis C as a function of mode of transmission. Hepatology 1998;28:562-567.
53. Degos F, Christidis C, Ganne-Carrie N, Farmachidi JP, Degott C, Guettier C, et al. Hepatitis C virus related cirrhosis: Time to occurrence of hepatocellular carcinoma and death. Gut 2000;47:131-136.
54. Serfaty L, Aumaitre H, Chazouilleres O, Bonnand AM, Rosmorduc O, Poupon RE, et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 1998;27:1435-1440.
55. Fattovich G, Giustina G, Schalm SW, Hadziyannis S, Sanchez-Tapias J, Almasio P, et al. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology 1995;21:77-82.
56. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995;346:1051-1055.
57. Tiribelli C, Melato M, Croce LS, Giarelli L, Okuda K, Ohnishi K. Prevalence of hepatocellular carcinoma and relation to cirrhosis: Comparison of two different cities of the world - Trieste, Italy, and Chiba, Japan. Hepatology 1989;10:998-1002.
58. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: National surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of hepatocarcinogenesis by interferon therapy. Ann Intern Med 1999;131:174-181.
59. De Bac C, Stroffolini T, Gaeta GB, Taliani G, Giusti G. Pathogenic factors in cirrhosis with and without hepatocellular carcinoma: A multicenter Italian study. Hepatology 1994;20:1225-1230.
60. Suzuki M, Suzuki H, Mizuno H, Tominaga T, Kono M, Kato Y, Sato A, et al. Studies on the incidence of hepatocellular carcinoma in heavy drinkers with liver cirrhosis. Alcohol Alcohol 1993;(Suppl 1B):109-114.
61. Mazzella G, Accogli E, Sottili S, Festi D, Orsini M, Salzetta A, et al. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 1996;24:141-147.
62. Niederau C, Lange S, Heintges T, Erhardt A, Buschkamp M, Hurter D, et al. Prognosis of chronic hepatitis C: Results of a large, prospective cohort study. Hepatology 1998;28:1687-1695.
63. Gramenzi A, Andreone P, Fiorino S, Camma C, Giunta M, Magalotti D, et al. Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis. Gut 2001;48:843-848.
64. Ikeda K, Saitoh S, Arase Y, Chayama K, Suzuki Y, Kobayashi M, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999;29:1124-1130.
65. Bruno S, Battezzati PM, Bellati G, Manzin A, Maggioni M, Crosignani A, et al. Long-term beneficial effects in sustained responders to interferon-alfa therapy for chronic hepatitis C. J Hepatol 2001;34:748-755.
66. International Interferon-alpha Hepatocellular Carcinoma Study Group. Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: A retrospective cohort study. Lancet 1998;351:1535-1539.
67. Imai Y, Kawata S, Tamura S, Yabuuchi I, Noda S, Inada M, et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group. Ann Intern Med 1998;129:94-99.
68. Valla DC, Chevallier M, Marcellin P, Payen JL, Trepo C, Fonck M, et al. Treatment of hepatitis C virus-related cirrhosis: A randomized, controlled trial of interferon alfa-2b versus no treatment. Hepatology 1999;29:1870-1875.
69. Okanoue T, Itoh Y, Minami M, Sakamoto S, Yasui K, Sakamoto M, et al. Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: A retrospective study in 1148 patients. Viral Hepatitis Therapy Study Group. J Hepatol 1999;30:653-659.
70. Papatheodoridis GV, Papadimitropoulos VC, Hadziyannis SJ. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: A meta-analysis. Aliment Pharmacol Ther 2001;15:689-698.
71. Camma C, Giunta M, Andreone P, Craxi A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: An evidence-based approach. J Hepatol 2001;34:593-602.
72. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745-750.
73. El-Serag HB, Mason AC, Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology 2001;33:62-65.
74. El-Serag HB. Global epidemiology of hepatocellular carcinoma. Liver Clin North Am 2001;5:87-107.
75. Davila J, Petersen N, Nelson H, El-Serag HB. Geographic variations in hepatocellular carcinoma [Abstract]. Gastroenterology 2002;122:A569.
76. El-Serag HB, Everhart JE. Improved survival after variceal hemorrhage over an 11-year period in the Department of Veterans Affairs. Am J Gastroenterol 2000;95:3566-3573.
77. El-Serag HB, Mason AC. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med 2000;160:3227-3230.
78. Okuda K. Hepatitis C virus and hepatocellular carcinoma. In: Okuda K, ed. Liver Cancer. New York: Churchill Livingstone, 1997;39-46.
79. Kiyosawa K, Tanaka E. Characteristics of hepatocellular carcinoma in Japan. Oncology 2002;62 (Suppl 1):5-7.
80. Mizokami M, Orito E, Tanaka Y, Lau JY, Suzuki Y. Divergence of hepatitis C virus in Japan versus United States estimated by molecular evolutionary analysis: Implications on health impact [Abstract]. Hepatology 1999;30:421A.
81. Kato Y, Hamasaki K, Aritomi T, Nakao K, Nakata K, Eguchi K. Most of the patients with cirrhosis in Japan die from hepatocellular carcinoma. Oncol Rep 1999;6:1273-1276.
82. Rapicetta M, Attili AF, Mele A, De Santis A, Chionne P, Cristiano K, et al. Prevalence of hepatitis C virus antibodies and hepatitis C virus-RNA in an urban population. J Med Virol 1992;37:87-92.
83. Guadagnino V, Stroffolini T, Rapicetta M, Costantino A, Kondili LA, Menniti-Ippolito F, et al. Prevalence, risk factors, and genotype distribution of hepatitis C virus infection in the general population: A community-based survey in southern Italy. Hepatology 1997;26:1006-1011.
84. Chiaramonte M, Stroffolini T, Lorenzoni U, Minniti F, Conti S, Floreani A, et al. Risk factors in community-acquired chronic hepatitis C virus infection: A case-control study in Italy. J Hepatol 1996;24:129-134.
85. La Vecchia C, Negri E, Pelucchi C. The rise and fall in primary liver cancer mortality in Italy. Dig Liver Dis 2002;34:169-171.
86. Alter MJ. Epidemiology of hepatitis C. Hepatology 1997;26:62S-65S.
87. Armstrong GL, Alter MJ, McQuillan GM, Margolis HS. The past incidence of hepatitis C virus infection: Implications for the future burden of chronic liver disease in the United States. Hepatology 2000;31:777-782.
88. Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000;90:1562-1569.